22-017
Showing 1 - 25 of 5,124
Low Back Pain Trial in Worldwide (Matching Placebo, Low Dose GRT6005, Medium Dose GRT6005)
Completed
- Low Back Pain
- Matching Placebo
- +4 more
-
Senftenberg, Austria
- +78 more
Jul 13, 2021
SARS-CoV-2 Infection, COVID-19 Trial in United Kingdom (SARS-CoV-2 rS/Matrix M1-Adjuvant, Placebo, Licensed seasonal influenza
Active, not recruiting
- SARS-CoV-2 Infection
- COVID-19
- SARS-CoV-2 rS/Matrix M1-Adjuvant
- +2 more
-
Belfast, Antrim, United Kingdom
- +32 more
Oct 19, 2022
COVID-19 Trial in Worldwide (LY3819253, Placebo, Remdesivir)
Completed
- COVID-19
- LY3819253
- +2 more
-
Tucson, Arizona
- +56 more
Mar 22, 2023
COVID-19 Trial in Worldwide (BRII-196, BRII-198, Placebo)
Completed
- COVID-19
- BRII-196
- +3 more
-
Tucson, Arizona
- +106 more
Mar 24, 2023
COVID-19 Trial in Worldwide (VIR-7831, Placebo, Remdesivir)
Completed
- COVID-19
- VIR-7831
- +2 more
-
Tucson, Arizona
- +104 more
Mar 22, 2023
COVID-19 Trial in Worldwide (AZD7442, Placebo, Remdesivir)
Active, not recruiting
- COVID-19
- AZD7442
- +2 more
-
Tucson, Arizona
- +123 more
Mar 24, 2023
Solid Tumor, Hematological Malignancy Trial in Australia (ATG-017)
Recruiting
- Solid Tumor
- Hematological Malignancy
-
East Melbourne, Victoria, Australia
- +4 more
Jan 11, 2023
NSCLC Trial in United States (Imprime PGG, MK-3475)
Active, not recruiting
- Non-Small Cell Lung Cancer
- Imprime PGG
- MK-3475
-
Chicago, Illinois
- +4 more
Oct 6, 2022
Advanced NSCLC, Metastatic Lung Cancer Trial in East Syracuse, Cleveland, Bellingham (Adagrasib in combination with
Recruiting
- Advanced NSCLC
- Metastatic Lung Cancer
- Adagrasib in combination with pembrolizumab
- Pembrolizumab
-
East Syracuse, New York
- +2 more
Nov 28, 2022
Diet, Autophagy Trial in San Antonio (Fasting Mimicking Diet)
Recruiting
- Diet
- Autophagy
- Fasting Mimicking Diet
-
San Antonio, TexasThe University of Texas Health Science Center at San Antonio
Oct 29, 2023
CT-based Myocardial Characterization (CTMyoC)
Recruiting
- Different Cardiomyopathy and Major Cardiovascular Adverse Events
-
Milano, ItalyIRCCS San Raffaele
Sep 1, 2023
Mucosal Melanoma Trial in New York (Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib)
Recruiting
- Mucosal Melanoma
- Nivolumab and/or Ipilimumab
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 14, 2022
Exercise Addiction, Diabetic Neuropathies Trial in Bangkok (Aerobic Thai dance exercise)
Completed
- Exercise Addiction
- Diabetic Neuropathies
- Aerobic Thai dance exercise
-
Bangkok, ThailandChulalongkorn university
Oct 2, 2023
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics Trial in West Bend (Clarithromycin, Pimozide, Placebo (Part 1))
Not yet recruiting
- Drug-induced QT Prolongation
- +2 more
- Clarithromycin
- +6 more
-
West Bend, WisconsinSpaulding Clinical Research
Feb 7, 2023
HIV Trial in Worldwide (Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel
Completed
- HIV
- Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
- +2 more
-
San Francisco, California
- +7 more
Jun 22, 2021
Dupilumab in Severe and Recurrent Nasosinusal Polyposis Despite
Not yet recruiting
- Chronic Rhinosinusitis With Nasal Polyps
- Questionnaires
-
Strasbourg, FranceHautepierre Hospital
Aug 29, 2023
Periodontitis, Diabetes, Type 2 Trial in Istanbul (Non-Surgical Periodontal Treatment)
Completed
- Periodontitis
- Diabetes Mellitus, Type 2
- Non-Surgical Periodontal Treatment
-
Istanbul, TurkeyMarmara University
Nov 11, 2023
Ankle Sprains, Chronic Pain Trial in Lahore (Group A - Closed Chain Exercise, Group B - Neuromuscular Training Exercise)
Completed
- Ankle Sprains
- Chronic Pain
- Group A - Closed Chain Exercise
- Group B - Neuromuscular Training Exercise
-
Lahore, Punjab, PakistanPakistan Sports Board
Jul 31, 2023
Fragile X Syndrome Trial in Australia, New Zealand, United States (ZYN002 - Cannabidiol Transdermal Gel)
Enrolling by invitation
- Fragile X Syndrome
- ZYN002 - Cannabidiol Transdermal Gel
-
Phoenix, Arizona
- +21 more
Aug 18, 2022
Influenza, Human, COVID-19 Trial in United States (bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV)
Recruiting
- Influenza, Human
- COVID-19
- bivalent BNT162b2 (original/Omi BA.4/BA.5)
- +2 more
-
Athens, Alabama
- +18 more
Dec 22, 2022
Autism Spectrum Disorder Trial (Exergaming, Booklet)
Not yet recruiting
- Autism Spectrum Disorder
- Exergaming
- Booklet
- (no location specified)
Jun 9, 2023